Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
PUMA BIOTECHNOLOGY INC · PHARMACEUTICAL PREPARATIONS · Now $7.12
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS